MRNA Tripled. Now It Has a $2.6B Offering.
Moderna’s Phase 3 melanoma win was historic. Days later, a convertible note deal is the real question investors must answer.
America’s Forgotten Energy Reserve
August 29, 2026 Bonus Content: Gilead’s Bixlenvo Is Approved. Now the Switch Math Begins. Sponsored Dear Reader, On a single…
ROIV Has Its First Approval. Now Comes the Harder Part.
Lisraya wins dermatomyositis, but a boxed warning, a larger patient pool than advertised, and Phase 3 readouts define what the stock is actually worth.
In at 9:35 AM. Out by 10.
August 29, 2026 Bonus Content: The IPO Window Is Open. Now the Fed May Slam It. Sponsored Hey, I’m going…
Make this ONE move to target beating rising costs
August 28, 2026 Bonus Content: 90 Billion Barrels. Now Comes the Hard Part. Sponsored Hi, I’m Alex Reid. I’m a…
When the Architect Wins in Space, Too
What Nvidia’s Starmind bet reveals about durable advantages and founders who compress time.
Gap’s 15% Pop Is a Tariff Refund in Disguise
August 28, 2026 Strip the 1,140bp IEEPA windfall and you find a 20bp margin business with half its revenue in…
Defined Levels for a Market Pulling Two Ways on Crude
Brent’s slide toward $88 and Trump’s hardline Iran turn set up two trades inside the same barrel.
The Investors Who Missed Nvidia. Here’s Your Second Chance
August 27, 2026 Bonus Content: The Grain Map Is Being Redrawn. ADM and Bunge Are Sitting on the Redline. Sponsored…
Ends Tonight: Tapping into a $2.1 trillion total addressable market
August 27, 2026 Bonus Content: Is Ulta’s Markdown Already in the Price? Sponsored In the world of high-growth energy tech,…